Incretin-based therapies for obesity treatment

Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane De Bona Schraiber, Gislaine Tezza Rezin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

Original languageEnglish (US)
Pages (from-to)967-981
Number of pages15
JournalMetabolism: Clinical and Experimental
Volume64
Issue number9
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Incretins
Obesity
Anti-Obesity Agents
Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
Weight Loss
Therapeutics
Public Health
Hormones
Diet
Pharmaceutical Preparations

Keywords

  • DPP-4
  • GLP-1
  • Incretin
  • Obesity
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Incretin-based therapies for obesity treatment. / Haas de Mello, Aline; Prá, Morgana; Cardoso, Larissa Colonetti; De Bona Schraiber, Rosiane; Rezin, Gislaine Tezza.

In: Metabolism: Clinical and Experimental, Vol. 64, No. 9, 01.01.2015, p. 967-981.

Research output: Contribution to journalArticle

Haas de Mello, A, Prá, M, Cardoso, LC, De Bona Schraiber, R & Rezin, GT 2015, 'Incretin-based therapies for obesity treatment', Metabolism: Clinical and Experimental, vol. 64, no. 9, pp. 967-981. https://doi.org/10.1016/j.metabol.2015.05.012
Haas de Mello, Aline ; Prá, Morgana ; Cardoso, Larissa Colonetti ; De Bona Schraiber, Rosiane ; Rezin, Gislaine Tezza. / Incretin-based therapies for obesity treatment. In: Metabolism: Clinical and Experimental. 2015 ; Vol. 64, No. 9. pp. 967-981.
@article{bcf66befc9d94f948d8724c83e400024,
title = "Incretin-based therapies for obesity treatment",
abstract = "Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.",
keywords = "DPP-4, GLP-1, Incretin, Obesity, Treatment",
author = "{Haas de Mello}, Aline and Morgana Pr{\'a} and Cardoso, {Larissa Colonetti} and {De Bona Schraiber}, Rosiane and Rezin, {Gislaine Tezza}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2015.05.012",
language = "English (US)",
volume = "64",
pages = "967--981",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Incretin-based therapies for obesity treatment

AU - Haas de Mello, Aline

AU - Prá, Morgana

AU - Cardoso, Larissa Colonetti

AU - De Bona Schraiber, Rosiane

AU - Rezin, Gislaine Tezza

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

AB - Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

KW - DPP-4

KW - GLP-1

KW - Incretin

KW - Obesity

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84939565602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939565602&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2015.05.012

DO - 10.1016/j.metabol.2015.05.012

M3 - Article

VL - 64

SP - 967

EP - 981

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -